- Home
- ZVRA vs AURA Comparison
ZVRA vs AURA Comparison
Compare ZVRA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- AURA
- Stock Information
- Founded
- ZVRA 2006
- AURA 2007
- Country
- ZVRA United States
- AURA United States
- Employees
- ZVRA N/A
- AURA N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- AURA Health Care
- Exchange
- ZVRA Nasdaq
- AURA Nasdaq
- Market Cap
- ZVRA 381.0M
- AURA 370.1M
- IPO Year
- ZVRA 2015
- AURA 2021
- Fundamental
- Price
- ZVRA $7.15
- AURA $5.36
- Analyst Decision
- ZVRA Strong Buy
- AURA Strong Buy
- Analyst Count
- ZVRA 8
- AURA 4
- Target Price
- ZVRA $22.29
- AURA $22.75
- AVG Volume (30 Days)
- ZVRA 542.5K
- AURA 482.7K
- Earning Date
- ZVRA 05-07-2025
- AURA 05-08-2025
- Dividend Yield
- ZVRA N/A
- AURA N/A
- EPS Growth
- ZVRA N/A
- AURA N/A
- EPS
- ZVRA N/A
- AURA N/A
- Revenue
- ZVRA $23,612,000.00
- AURA N/A
- Revenue This Year
- ZVRA $267.44
- AURA N/A
- Revenue Next Year
- ZVRA $90.10
- AURA N/A
- P/E Ratio
- ZVRA N/A
- AURA N/A
- Revenue Growth
- ZVRA N/A
- AURA N/A
- 52 Week Low
- ZVRA $4.20
- AURA $4.84
- 52 Week High
- ZVRA $9.76
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- ZVRA 45.68
- AURA 37.19
- Support Level
- ZVRA $6.77
- AURA $4.84
- Resistance Level
- ZVRA $7.22
- AURA $5.82
- Average True Range (ATR)
- ZVRA 0.45
- AURA 0.48
- MACD
- ZVRA -0.00
- AURA 0.03
- Stochastic Oscillator
- ZVRA 61.74
- AURA 32.20
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.